arrow
Return

Protocol implementation during the COVID-19 pandemic: experiences from a randomized trial of stress ulcer prophylaxis

delete2024-05-04
delete1
delete
OA
AI
B
Brittany B. Dennis
A
Adam M. Deane
F
François Lauzier
N
Nicole Zytaruk
M
M.J. Hardie
N
Naomi Hammond
S
Simon Finfer
Y
Yaseen M. Arabi
J
John C. Marshall
L
Lois Saunders
D
Diane Heels‐Ansdell
J
John Myburgh
S
Serena Knowles
J
John Muscedere
M
Marlies Ostermann
D
Dorrilyn Rajbhandari
S
Shane English
K
Karlo Matic
B
Balasubramanian Venkatesh
A
Abdulrahman Al Fares
G
Gordon Guyatt
W
Waleed Alhazzani
H
Hassan Mumtaz
A
Alexis Poole
F
Feng Xie
L
Lehana Thabane
R
Richard Hall
D
Deborah Cook *
DOI:10.1186/s12874-024-02233-2delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Background During the COVID-19 pandemic, many intensive care units (ICUs) halted research to focus on COVID-19-specific studies. Objective To describe the conduct of an international randomized trial of stress ulcer prophylaxis (Re-Evaluating the Inhibition of Stress Erosions in the ICU [REVISE]) during the pandemic, addressing enrolment patterns, center engagement, informed consent processes, data collection, a COVID-specific substudy, patient transfers, and data monitoring. Methods REVISE is a randomized trial among mechanically ventilated patients, comparing pantoprazole 40 mg IV to placebo on the primary efficacy outcome of clinically important upper gastrointestinal bleeding and the primary safety outcome of 90-day mortality. We documented protocol implementation status from March 11th 2020-August 30th 2022. Results The Steering Committee did not change the scientific protocol. From the first enrolment on July 9th 2019 to March 10th 2020 (8 months preceding the pandemic), 267 patients were enrolled in 18 centers. From March 11th 2020-August 30th 2022 (30 months thereafter), 41 new centers joined; 59 were participating by August 30th 2022 which enrolled 2961 patients. During a total of 1235 enrolment-months in the pandemic phase, enrolment paused for 106 (8.6%) months in aggregate (median 3 months, interquartile range 2;6). Protocol implementation involved a shift from the a priori consent model pre-pandemic (188, 58.8%) to the consent to continue model (1615, 54.1%, p < 0.01). In one new center, an opt-out model was approved. The informed consent rate increased slightly (80.7% to 85.0%, p = 0.05). Telephone consent encounters increased (16.6% to 68.2%, p < 0.001). Surge capacity necessitated intra-institutional transfers; receiving centers continued protocol implementation whenever possible. We developed a nested COVID-19 substudy. The Methods Centers continued central statistical monitoring of trial metrics. Site monitoring was initially remote, then in-person when restrictions lifted. Conclusion Protocol implementation adaptations during the pandemic included a shift in the consent model, a sustained high consent rate, and launch of a COVID-19 substudy. Recruitment increased as new centers joined, patient transfers were optimized, and monitoring methods were adapted.
Keywords:
Randomization
Critically ill
COVID-19 Pandemic
Hospital transfers
Stress ulceration
Gastrointestinal bleeding
Ventilator-associated pneumonia
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

BMC Medical Research Methodology cover
BMC Medical Research Methodology
IF:
3.4
Papers:
3.9K
Citations:
2.8W

Organization

S
St George Hospital
Scholars:
1.6K
Papers: 1.2K
Citations: 2
G
George Institute for Global Health
Scholars:
2.6K
Papers: 2.5K
Citations: 628
M
Monash University
Scholars:
5.4W
Papers: 5.4W
Citations: 79
O
Ottawa Hospital Research Institute
Scholars:
6.5K
Papers: 5.2K
Citations: 1.3W
L
laval university
Scholars:
2.5W
Papers: 2.2W
Citations: 96
K
King Saud bin Abdulaziz University for Health Sciences
Scholars:
5.4K
Papers: 2.8K
Citations: 2.3K
U
university of london
Scholars:
21.3W
Papers: 19.6W
Citations: 305
M
McMaster University
Scholars:
3.6W
Papers: 3.3W
Citations: 4.4W
U
University of Ottawa
Scholars:
3.5W
Papers: 3.1W
Citations: 3.8W
U
university of melbourne
Scholars:
5.6W
Papers: 5.4W
Citations: 69
U
university of toronto
Scholars:
14.5W
Papers: 11.9W
Citations: 165
researcher View more organizations